Berotralstat is indicated for the routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/05/2022|
|Rapid review completed||03/06/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of berotralstat compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|